BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Macrocure Selected to Present Scientific Poster at 2013 Symposium on Advanced Wound Care (SAWC)


4/29/2013 11:45:11 AM

PETACH TIKVA, Israel – April 29, 2013 – Macrocure (www.macrocure.com), a biotechnology company developing advanced cell therapy products, announced today that Dr. Latricia Allen, a physician in the group of Dr. Vickie R. Driver DPM, will present a poster focusing on the positive results of a recent study conducted with the company’s flagship product, CureXcell®, at the Symposium on Advanced Wound Care - Wound Healing Society’s Annual Meeting, May 1-5 in Denver, Colorado.

The poster Dr. Allen will present is titled, “A prospective multi-center 24 week observational study evaluating wound healing outcomes in 131 patients in seven community wound care clinics in the largest HMO In Israel, treated with human activated leukocytes suspension, CureXcell." The poster summarizes the results of a phase-IV study in adult patients with chronic wounds (diabetic foot ulcers, pressure ulcers, venous ulcers, post-operative ulcers), resulting in approximately 70% of the wounds being closed within 24 weeks. The conclusion of the study was that CureXcell appears to be both safe and effective in healing chronic wounds. The poster will be available for viewing throughout the conference.

“We are very proud that Macrocure was chosen to present at SAWC as it provides the company with a wonderful opportunity to demonstrate our revolutionary technology to the world’s leading wound care scientists,” said Nissim Mashiach, President and CEO of Macrocure. “This is yet another indication that our research is advancing the treatment of hard-to-heal wounds and we look forward to continuing to present strong results from the studies and trials we are currently conducting.”

Macrocure will be co-sponsoring an accredited educational session on May 4 at 3:30 p.m. titled, "Today’s Science is Tomorrow’s New Treatment Option: Emerging Cell-Based Therapy for Difficult-to-Heal Wounds." The session will be led by Dr. Vickie R. Driver DPM and Dr. Robert J. Snyder. Dr. Driver is the Podiatric Surgery Division Chief and Research Program Director-Limb Preservation and Wound Healing, VA New England Health Care Division, and is President Elect for the Association for the Advancement of Wound Care (AAWC). Dr. Snyder is the Director of Clinical Research, School of Podiatric Medicine at Barry University in Miami Shores, Florida and the President of the Association for the Advancement of Wound Care.

For more information about the SAWC conference, please visit www.woundheal.org/annual-meeting.

About Macrocure

Macrocure is a biotechnology company which focuses on the development and commercialization of advanced wound care therapies. Macrocure is pursuing regulatory market approval in North America and Europe. CureXcell is also currently undergoing a Phase III randomized, double-blind trial for lower extremity chronic ulcers in adults with diabetes in the United States, Canada and Israel. The product has marketing authorization in Israel for the treatment of chronic ulcers, but is not yet licensed for sale in either the United States or Canada.

About CureXcell®

CureXcell ® is an innovative, advanced wound care product comprised of activated allogeneic immune cells that are superficially injected into the wound bed, once a month.

CureXcell® provides the solution for impaired wound healing by introducing the right combination of activated cells required to restore normal wound healing processes and achieve full wound closure.

Media Contact:

Matthew Krieger

Finn Partners Israel for Macrocure

+972-544-676-950

matthew@finnpartners.co.il



Read at BioSpace.com

Macrocure
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES